The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.
No linked publications found in PubMed
Inclusion Criteria: * Have received or plan to receive pegcetacoplan for the treatment of C3G or primary IC-MPGN. * Provided signed and dated informed consent. For participants under the legal age signed and dated informed consent is provided by the participant's legally authorised representative. Assent will also be obtained from paediatric participants as required by local regulations. Exclusion Criteria: * Receiving an investigational treatment for C3G or primary IC-MPGN at the time of pegcetacoplan initiation. * Initiated treatment with pegcetacoplan in an interventional study.